New targeted drug shows promise for BRAF-Mutant cancers in early trial
Disease control
Completed
This early-stage trial tested a new drug called CFT1946, alone or with other drugs, in 89 adults with solid tumors that have a BRAF V600 mutation, including melanoma, lung, colon, and thyroid cancers. The main goals were to check safety and find the best dose. The study is comple…
Phase: PHASE1 • Sponsor: C4 Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC